Patient Selection in EBC-46 Trials: Who Qualifies and Why Inclusion Criteria Matter
Clinical trials of tigilanol tiglate use strict inclusion and exclusion criteria to identify patients most likely to respond safely, shaping the evidence base for EBC-46 research.
Every clinical trial begins with a fundamental question: which patients should be enrolled? For tigilanol tiglate (EBC-46), the answer has shaped the trajectory of human research from the earliest Phase I safety studies through to ongoing Phase II efficacy trials. Understanding patient selection criteria provides important context for interpreting trial results and for anticipating how EBC-46 research may evolve.
Phase I: Establishing Safety in Advanced Disease
The first human trial of tigilanol tiglate, conducted by QBiotics Group, enrolled patients with advanced solid tumours who had exhausted standard treatment options. This is standard practice in oncology Phase I trials: patients with limited alternatives are offered experimental treatments, allowing researchers to assess safety, tolerability, and preliminary efficacy. The trial used intratumoral injection of pharmaceutical-grade tigilanol tiglate into cutaneous and subcutaneous lesions — tumours accessible on or just below the skin surface.
Inclusion criteria typically required measurable, accessible lesions, adequate organ function (liver, kidney, bone marrow), and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, indicating patients well enough to tolerate treatment and attend follow-up visits. Exclusion criteria ruled out patients with bleeding disorders, active infections at the injection site, or tumours in anatomically risky locations.
Why Cutaneous and Subcutaneous Tumours
Tigilanol tiglate's mechanism of action — local vascular disruption and haemorrhagic necrosis — requires direct injection into the tumour mass. This means that, for safety and practical reasons, early trials focus on tumours that are visible, measurable, and accessible. Cutaneous melanoma, squamous cell carcinoma, and other skin-accessible malignancies have been primary targets. This is consistent with the development pathway used for other intratumoral therapies, including talimogene laherparepvec (T-VEC), which received FDA approval for injectable melanoma treatment.
Dose Escalation and Response Assessment
Phase I trials used a standard dose-escalation design, starting with low doses and gradually increasing to identify the maximum tolerated dose. Response was assessed using modified RECIST criteria — measuring changes in tumour diameter at defined intervals after injection. Published data indicated that a subset of patients achieved complete responses (total disappearance of the injected lesion), while others showed partial responses or stable disease. These results informed dose selection for subsequent trials.
Expanding Eligibility: Phase II and Beyond
As safety data accumulates, trial eligibility criteria are expected to broaden. Phase II trials may include patients with earlier-stage disease, different tumour types, or lesions in additional anatomical locations. The ClinicalTrials.gov registry provides updated information on active and planned tigilanol tiglate studies, including current eligibility requirements for potential participants.
What Trial Criteria Mean for Supplement Consumers
It is important to note that clinical trial data for tigilanol tiglate is generated using pharmaceutical-grade injectable material under controlled clinical conditions. Dietary supplements containing blushwood berry extract are a distinct product category, manufactured under DSHEA and not intended to replicate clinical trial protocols. Consumers interested in blushwood berry extract supplements should consult a healthcare professional and understand that supplement products are not intended to diagnose, treat, cure, or prevent any disease.
Related Articles
For further reading on EBC-46 clinical research, see our analysis of Phase I/II data and adverse event profiles in tigilanol tiglate trials.
